摘要
目的评价曲美他嗪联合麝香保心丸对老年心绞痛患者的治疗效果以及老年稳定型心绞痛患者口服曲美他嗪耐受性与安全性。方法选取100例老年心绞痛患者为研究对象,分为治疗组(50例)与对照组(50例)。对照组采用冠心病基础用药包括抗血小板、调脂、硝酸酯类,β受体阻滞剂;治疗组在原有冠心痛基础用药上加口服曲美他嗪每日3次,每次20mg,麝香保心丸每日3次,每次3粒,共3个月。随访3个月,观察2组患者用药的耐受性、心绞痛发作频率,疼痛时间,治疗前后血脂的变化,左室舒张末期内径及左室射血分数及药物不良反应。结果治疗3个月后,患者心绞痛持续时间及疼痛程度减轻,发作频率减少,左室舒张末期内径明显缩小,左室射血分数明显改善,与治疗前比较差异具有统计学意义(P<0.05)100例患者均未发生不良反应。结论曲美他嗪联合麝香保心丸可明显缓解老年心绞痛患者的心绞痛症状及改善左室舒张末期内径及功能,冠心病患者长期服用曲美他嗪的临床耐受性和安全性良好。
Objective To research the therapeutic effects of Trimetazidine combined with Shexiang Baoxin Pills in elderly patients with Coronary Heart Disease of Stable Angina Pectoris. Methods There are 100 eases elderly patients with Coronary Heart Disease of Stable Angina Pectoris, 50 eases are in the observation group, the others are in the control group. All cases are given the con- ventional basis of anti-angina drugs. Besides these traditional therapy, the observation group are given Trimetazidine 20mg tid & Shexiang Baoxin Pills 3 pills tid additionally. Results After the continuous treatment for 3 months, the overall effective rate of ob- servation group was significantly higher than that of routine treatment group, P〈0.05. There is none of any adverse reaction in all cases. Conclusion Trimetazidine combined with Shexiang Baoxin Pills can significantly alleviate the multi-vessel disease, coronary heart disease in patients with angina pectoris. And this therapy is well tolerated and safe.
出处
《中国卫生产业》
2012年第14期6-7,共2页
China Health Industry
关键词
心绞痛
曲美他嗪麝香保心丸
耐受性
安全性
Stable Angina Peetoris
Trimetazidine Shexiang Baoxin Pills
Tolerability
Safety